SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Disaggregation of Revenue [Line Items] |
|
| Schedule of percentages of deferred revenue by year |
| | | | | | Revenue | | Year: | | Recognition | | 2026 | | 91 | % | 2027 | | 3 | % | 2028 | | — | % | 2029 | | 6 | % | Total | | 100 | % |
|
| Schedule of revenue generated in geographic regions for years indicated |
The following geographic data includes revenue generated from the Company’s third-party distributors. The Company’s revenue was generated in the following geographic regions and by product line for the periods indicated (in thousands): | | | | | | | | | | | | | | | Revenues by Geography | | | | | Year ended December 31, | | | | | 2025 | | 2024 | | | | | | | | % of | | | | | % of | | | | | Amount | | Revenues | | Amount | | Revenues | | | | | | (in thousands, except percentages) | | | U.S. | | $ | 146,048 | | 98 | % | $ | 72,488 | | 97 | % | | International | | | 3,109 | | 2 | % | | 2,402 | | 3 | % | | Total revenues | | $ | 149,157 | | 100 | % | $ | 74,890 | | 100 | % | |
| | | | | | | | | | | | | | Revenues by Geography | | | | Year ended December 31, | | | | 2024 | | 2023 | | | | | | | % of | | | | | % of | | | | Amount | | Revenues | | Amount | | Revenues | | | | | (in thousands, except percentages) | | United States | | $ | 72,488 | | 97 | % | $ | 69,336 | | 97 | % | International | | | 2,402 | | 3 | % | | 2,012 | | 3 | % | Total revenues | | $ | 74,890 | | 100 | % | $ | 71,348 | | 100 | % |
|
| U.S. |
|
| Disaggregation of Revenue [Line Items] |
|
| Schedule of revenue generated in product category for years indicated |
| | | | | | | | | | | | | | U.S. Revenues by Product Category | | | | Year ended December 31, | | | | 2025 | | 2024 | | | | | | | % of | | | | % of | | | | Amount | | Revenues | | Amount | | Revenues | | | | | (in thousands, except percentages) | | NeuroStar Advanced Therapy System | | $ | 14,259 | | 10 | % | $ | 15,267 | | 21 | % | Treatment sessions | | | 43,319 | | 30 | % | | 50,832 | | 70 | % | Clinic revenue | | | 86,977 | | 59 | % | | 4,445 | | 6 | % | Other | | | 1,493 | | 1 | % | | 1,944 | | 3 | % | Total U.S. revenues | | $ | 146,048 | | 100 | % | $ | 72,488 | | 100 | % |
| | | | | | | | | | | | | | U.S. Revenues by Product Category | | | | Year ended December 31, | | | | 2024 | | 2023 | | | | | | | % of | | | | | % of | | | | Amount | | Revenues | | Amount | | Revenues | | | | | (in thousands, except percentages) | | NeuroStar Advanced Therapy System | | $ | 15,267 | | 21 | % | $ | 16,460 | | 24 | % | Treatment sessions | | | 50,832 | | 70 | % | | 50,896 | | 73 | % | Clinic revenue | | | 4,445 | | 6 | % | | — | | — | % | Other | | | 1,944 | | 3 | % | | 1,980 | | 3 | % | Total U.S. revenues | | $ | 72,488 | | 100 | % | $ | 69,336 | | 100 | % |
|
| International |
|
| Disaggregation of Revenue [Line Items] |
|
| Schedule of revenue generated in product category for years indicated |
| | | | | | | | | | | | | | International Revenues by Product Category | | | | Year ended December 31, | | | | 2025 | | 2024 | | | | | | | % of | | | | | % of | | | | Amount | | Revenues | | Amount | | Revenues | | | | | (in thousands, except percentages) | | NeuroStar Advanced Therapy System | | $ | 1,276 | | 41 | % | $ | 826 | | 34 | % | Treatment sessions | | | 1,088 | | 35 | % | | 613 | | 26 | % | Other | | | 745 | | 24 | % | | 963 | | 40 | % | Total International revenues | | $ | 3,109 | | 100 | % | $ | 2,402 | | 100 | % |
| | | | | | | | | | | | | | International Revenues by Product Category | | | | Year ended December 31, | | | | 2024 | | 2023 | | | | | | | % of | | | | | % of | | | | Amount | | Revenues | | Amount | | Revenues | | | | | (in thousands, except percentages) | | NeuroStar Advanced Therapy System | | $ | 826 | | 34 | % | $ | 629 | | 31 | % | Treatment sessions | | | 613 | | 26 | % | | 754 | | 38 | % | Other | | | 963 | | 40 | % | | 629 | | 31 | % | Total International revenues | | $ | 2,402 | | 100 | % | $ | 2,012 | | 100 | % |
|